SYRE vs ARRY vs PRTA

For growth investors, Array Technologies, Inc.

(ARRY) is the stronger pick with 40. 2% revenue growth year-over-year, versus -92. 8% for Prothena Corporation plc (PRTA). Analysts rate Spyre Therapeutics, Inc. (SYRE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Prothena Corporation plc (PRTA) delivered a total return of -57.

2%, compared to -67. 7% for Array Technologies, Inc. (ARRY). Over 10 years, the gap is even starker: SYRE returned -66. 8% versus ARRY's -77. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Prothena Corporation plc (PRTA) is the lower-risk stock at 0.

96β versus Array Technologies, Inc. 's 2. 32β — meaning ARRY is approximately 141% more volatile than PRTA relative to the S&P 500. On balance sheet safety, Prothena Corporation plc (PRTA) carries a lower debt/equity ratio of 5% versus 3% for Array Technologies, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Array Technologies, Inc.

(ARRY) is pulling ahead at 40. 2% versus -92. 8% for Prothena Corporation plc (PRTA). On earnings-per-share growth, the picture is similar: Array Technologies, Inc. grew EPS 62. 6% year-over-year, compared to -99. 6% for Prothena Corporation plc. Over a 3-year CAGR, ARRY leads at -7. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Array Technologies, Inc.

(ARRY) is the more profitable company, earning -4. 1% net margin versus -25. 2% for Prothena Corporation plc — meaning it keeps -4. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ARRY leads at 6. 6% versus -1905. 8% for PRTA. At the gross margin level — before operating expenses — PRTA leads at 61. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Array Technologies, Inc.

(ARRY) trades at 11. 7x forward P/E versus 42. 7x for Prothena Corporation plc — 30. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRTA: 80. 4% to $19. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Prothena Corporation plc (PRTA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

96)). Array Technologies, Inc. (ARRY) carries a higher beta of 2. 32 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PRTA: -73. 0%, ARRY: -77. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SYRE (Healthcare) and ARRY (Energy) and PRTA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SYRE is a mid-cap quality compounder stock; ARRY is a small-cap high-growth stock; PRTA is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.